Clinical Trial Update: Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating camrelizumab plus doxorubicin as first-line treatment for advanced soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue | Phase 2 | Status: UNKNOWN